© 2020 MJH Life Sciences and Managed Healthcare Executive. All rights reserved.
Biosimilars
Biosimilars Fan Club Includes Free-Market Conservatives
July 06, 2020
Pacific Research Institute’s Winegarden Sees Dose of Competition as Way to Lower OOP Costs
Survey: Rheumatologists Still Reluctant to Switch Patients to Biosimilars
July 02, 2020
Cardinal Health recently conducted a survey of more than 100 rheumatologists asking their feelings about biosimilars, and the findings revealed that the majority of them were familiar with and comfortable prescribing biosimilars.
Challenges of Developing the Next Generation of Biosimilars
June 04, 2020
Proving therapeutic equivalence is a major hurdle.
Understanding Biosimilar Development and Approvals
June 04, 2020
Developing a biosimilar can be more challenging than developing the innovator product because of the need to match the attributes of a highly complex molecules.
11 Trends Influencing Biosimilars in 2020
May 18, 2020
The purpose of biosimilar is simple: reduce healthcare costs, pure and simple. Here are 11 trends affecting biosimilars over the last year in the U.S.
Health Execs: Here are 5 Important Takeaways About the Current Situation With Biosimilars
May 18, 2020
Just as we’ve seen the entire healthcare landscape change in 2020 because of COVID-19, the world of biosimilars is ever-changing.
Biosimilars in the Pipeline
January 02, 2020
Several biosimilars will come to market within the next few years.
Biosimilar Availability May Impact Drug Pricing
January 02, 2020
Study finds that biologics that faced competition from biosimilars showed reductions in net prices and leveling off of list price increases.
3 Ways Insurers Can Help Promote Biosimilar Adoption
May 01, 2019
The FDA Commissioner says that insurers can help biosimilar adoption by taking short-term financial losses over long-term drug savings. What else should they be doing?